便微生物群移植:一种对2型糖尿病的潜在治疗方法
相关实验视频
Updated: Jul 3, 2025
07:32
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
4.0K
Xiaolan Zhou1, Rumeng Chen2, Yichen Cai1
1Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Diabetes, metabolic syndrome and obesity : targets and therapy
|February 13, 2024
概括
胃肠道微生物组在2型糖尿病 (T2DM) 中发挥着作用. 便微生物种移植 (FMT) 通过调节肠道微生物群,显示了T2DM治疗的潜力,但需要进一步研究.
科学领域:
- 微生物学 微生物学
- 代谢疾病 代谢疾病
- 胃肠病学 胃肠病学
背景情况:
- 胃肠道微生物组 (GM) 与2型糖尿病 (T2DM) 的发展有关.
- 转基因代谢物,如短链脂肪酸和三甲基胺N-氧化物,会影响宿主代谢.
- 转基因失调是T2DM发病的一个重要因素.
研究的目的:
- 审查GM在T2DM发展中的作用.
- 评估用于T2DM治疗的便微生物群移植 (FMT) 的可行性.
- 建议对T2DM管理中的FMT应用进行改进.
主要方法:
- 对转基因,T2DM和FMT研究的文献综述.
- 对在代谢性疾病模型和人类实验对 FMT 疗效的现有研究进行分析.
- 综合信息来评估FMT对T2DM的潜力和局限性.
主要成果:
- 转基因失调与T2DM密切相关.
- 在临床前和一些临床研究中,FMT在治疗代谢性疾病 (包括T2DM) 方面表现有前途.
- 目前直接支持FMT治疗T2DM的证据有限,并且缺乏标准化.
结论:
- 通过FMT调节GM可能会改善T2DM患者的胰岛素抵抗和血糖控制.
- FMT代表了T2DM潜在的未来治疗选择.
- 为了确定T2DM治疗中FMT的疗效,安全性和最佳方案,进一步的研究是必不可少的.
相关概念视频
01:50What is Monogastric Digestion?
71.2K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
71.2K
01:15Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285